Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Multiple sclerosis care is evolving fast, with updated diagnostic criteria and a shift toward early high-efficacy treatment. The 2024 McDonald criteria revisions allow earlier, more confident MS diagnoses — even before symptoms worsen. Meanwhile, the field is increasingly moving away from a "start low, escalate later" treatment approach in favor of hitting the disease hard from the start.
Multiple sclerosis diagnosis and management are undergoing significant changes, and clinicians are being urged to catch up. The 2024 revisions to the McDonald diagnostic criteria now allow neurologists to identify MS earlier and with greater precision — without waiting for neurological worsening to confirm the diagnosis.
On the treatment side, the field has largely shifted away from the traditional escalation approach (start with lower-efficacy drugs, move up if needed) toward early high-efficacy therapy. This means more patients are being started on infusion or injection-based treatments right after diagnosis, with the goal of not just reducing relapses but also slowing long-term disease progression.
Key Takeaways:
Why it matters: Earlier diagnosis means earlier treatment, which translates to less disability over time. As the field moves toward more aggressive upfront therapy, clinicians need to stay current on both the evolving diagnostic landscape and the growing pipeline of therapies targeting disease progression.
